Noven Pharmaceuticals Inc. Announces Settlement Of Lidoderm® Patent Litigation

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MIAMI & NEW YORK--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc. today announced that it has entered into an agreement with Endo Pharmaceuticals Inc., Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc. to settle all outstanding patent litigation related to Noven’s lidocaine topical patch 5% product. An Abbreviated New Drug Application for Noven’s product is currently pending at the U.S. Food and Drug Administration (FDA). If approved, Noven’s product would be a generic version of Endo’s Lidoderm®.

Help employers find you! Check out all the jobs and post your resume.

Back to news